Table 1 Clinico-pathological characteristics of the 542 ovarian tumors
From: A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors
Characteristics | HGSC (n = 114) | LGSC (n = 100) | mSBT (n = 41) | EC (n = 54) | CCC (n = 124) | MBT (N = 75) | MC (N = 34) |
|---|---|---|---|---|---|---|---|
Age (years) | |||||||
Median | 60 | 55 | 49 | 54 | 62 | 51 | 58 |
No. of patients < median | 55 (48.2%) | 45 (45%) | 15 (35.7%) | 25 (46.3%) | 57 (46.0%) | 35 (46.7%) | 16 (47.1%) |
No. of patients ≥ median | 59 (51.8%) | 47 (47%) | 18 (42.8%) | 25 (46.3%) | 65 (52.4%) | 35 (46.7%) | 16 (47.1%) |
NA | 0 (0%) | 8 (8%) | 9 (21.5%) | 4 (7.4%) | 2 (1.6%) | 5 (6.6%) | 2 (5.8%) |
FIGO | |||||||
IA | 1 (0.9%) | 2 (2%) | 3 (7.3%) | 20 (37.0%) | 40 (32.3%) | 59 (78.7%) | 14 (41.2%) |
IB | 4 (3.5%) | 1 (1%) | 3 (7.3%) | 6 (11.1%) | 1 (0.8%) | 0 (0%) | 1 (2.9%) |
IC | 4 (3.5%) | 11 (11%) | 5 (12.2%) | 19 (35.2%) | 39 (31.5%) | 14 (18.6%) | 11 (32.4%) |
II (IIA + IIB) | 7 (6.1%) | 6 (6%) | 2 (4.9%) | 3 (5.6%) | 10 (8%) | 0 (0%) | 1 (2.9%) |
III | 68 (59.6%) | 52 (52%) | 16 (39%) | 3 (5.6%) | 24 (19.4%) | 0 (0%) | 6 (17.6%) |
IV | 28 (24.6%) | 2 (2%) | 0 (0%) | 1 (1.9%) | 1 (0.8%) | 1 (1.3%) | 1 (2.9%) |
NA | 2 (1.8%) | 26 (26%) | 12 (29.3%) | 2 (3.7%) | 9 (7.3%) | 1 (1.3%) | 0 (0%) |
T stage | |||||||
T1a | 3 (2.6%) | 2 (2%) | 3 (7.3%) | 21 (38.9%) | 40 (32.3%) | 59 (78.7%) | 14 (41.2%) |
T1b | 5 (4.4%) | 1 (1%) | 3 (7.3%) | 6 (11.1%) | 1 (0.8%) | 0 (0%) | 1 (2.9%) |
T1c | 5 (4.4%) | 11 (11%) | 5 (12.2%) | 19 (35.2%) | 41 (33%) | 14 (18.6%) | 11 (32.4%) |
T2 | 13 (11.4%) | 6 (6%) | 2 (4.9%) | 3 (5.6%) | 12 (9.7%) | 0 (0%) | 1 (2.9%) |
T3 | 85 (74.6%) | 53 (53%) | 16 (39%) | 3 (5.6%) | 22 (17.7%) | 1 (1.3%) | 7 (20.6%) |
NA | 3 (2.6%) | 27 (27%) | 12 (29.3%) | 2 (3.7%) | 8 (6.5%) | 1 (1.3%) | 0 (0%) |
Lymph node involvement | |||||||
N0 | 29 (25.4%) | 17 (17%) | 12 (29.3%) | 40 (74.1%) | 53 (42.7%) | 9 (12%) | 12 (35.3%) |
N1 | 44 (38.6%) | 20 (20%) | 3 (7.3%) | 1 (1.9%) | 7 (5.7%) | 0 (0%) | 3 (8.8%) |
NA | 41 (36%) | 63 (63%) | 26 (64.4%) | 13 (24.0%) | 64 (51.6%) | 66 (88%) | 19 (55.9%) |